Biosimilars

Top news of the week from Specialty Pharmacy Times.

Switching from etanercept to biosimilar was not associated with treatment-emergent adverse events in rheumatoid arthritis.

Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.

There remain significant issues for biosimilars to impact the drug market in the United States.

Biosimilar uptake in the United States still faces significant challenges.

The guidance describes chemistry, manufacturing, and controls postapproval manufacturing changes considered to have minimal potential to adversely affect quality.

Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses how education and counseling can improve the uptake of biosimilars among rheumatologists and patients.

The launch of a second Remicade biosimilar could open the floodgates to biosimilar competition in the specialty drug market.

New guidelines and standards have facilitated a robust pipeline of biosimilars in the United States.

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Biosimilar to trastuzumab (Herceptin) observed to have no clinically significant differences than the reference product.

Trastuzumab is indicated as an adjuvant therapy for HER2-positive breast cancer, along with metastatic breast and gastric cancers.

New report provides insight into patient awareness and attitudes towards biosimilars.

Biosimilars have the potential to achieve billions in savings, but significant challenges remain.

Express Scripts reports that the emergence of 11 biosimilars could result in $250 billion in savings over the next decade.

Study finds the current reimbursement model for biosimilars needs to be adjusted to improve uptake.

Filgrastim-sndz (Zarxio) is covered by 94% of employer-sponsored health plans.

The ability of manufacturers to convey the efficacy and safety of a new biosimilar is crucial.

Boehringer Ingelheim seeks to launch its biosimilar to Humira.

Changing from a biologic to a biosimilar can create insecurity among patients with RA.

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses how to increase the utilization of biosimilars across the industry.

Erelzi (etanercept) indicated to treat multiple inflammatory conditions.

Payers and providers may be less likely to encourage the use of biosimilars due to multiple concerns.

There are nearly 1000 products in development for dermatological conditions.